0
Abstract: Slide Presentations |

Chronic Use of Anti-gastroesophageal Reflux (GER) Medications in Patients with Idiopathic Pulmonary Fibrosis (IPF) FREE TO VIEW

Williamson Z. Bradford, MD, PhD; Kevin K. Brown, MD; Paul W. Noble, MD; Karen M. Starko, MD; David A. Schwartz, MD; Ganesh Raghu, MD*; Sharon Safrin, MD; Derek Weycker, PhD
Author and Funding Information

University of Washington Medical Center, Seattle, WA


Chest


Chest. 2004;126(4_MeetingAbstracts):772S. doi:10.1378/chest.126.4_MeetingAbstracts.772S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  IPF is a fatal disorder with no proven treatment. Studies have linked GER with reduced gas transfer (Schachter ATS 2001) and showed an increased prevalence of GER in IPF (Tobin AJRCCM 1998). Anti-GER therapy has been recommended in IPF (Kairalla ATS 2003). We sought to examine the frequency of chronic anti-GER use in IPF patients and its relationship to outcome.

METHODS:  We retrospectively analyzed data from a randomized trial evaluating interferon gamma-1b (IFN-gamma 1b) in IPF patients (Raghu NEJM 2004). Chronic anti-GER use was defined as >= 6 months non-prn use of any antacid, sucralfate, H2 blocker, or proton pump inhibitor at study entry; non-users had < 6 months of use or none. Cox proportional hazards regression was used to examine the relationship between chronic anti-GER use and death, disease progression (defined as >= 10% FVC decrease), and hospitalization, while controlling for age, baseline FVC, and use of IFN-gamma 1b.

RESULTS:  85 patients used chronic anti-GER medications, in varying doses; 177 patients were non-users. Median follow-up was ∼72 weeks. Rates of death, disease progression, and hospitalization were not significantly different in anti-GER users than non-users. Multivariate analyses found no association between anti-GER use and either death or disease progression. However, anti-GER use was an independent predictor of hospitalization (hazard ratio (HR) 1.9; p = 0.02) and respiratory hospitalization (HR 2.2; p = 0.02). No interaction of anti-GER therapy with use of IFN-gamma 1b was found.

CONCLUSION:  A substantial proportion (32%) of IPF patients received anti-GER treatments chronically. Although no effect on mortality or disease progression was evident, there was an increased risk of hospitalization and respiratory hospitalization in chronic anti-GER users. Since this study was not designed to assess anti-GER efficacy in IPF patients, cause and effect cannot be determined.

CLINICAL IMPLICATIONS:  Rigorous controlled trials with 24-hour pH esophageal monitoring and evaluation for aspiration are necessary to definitively determine the effect of reducing gastric acid and anti-GER therapy on outcome of IPF.

DISCLOSURE:  G. Raghu, Funding provided by InterMune, Inc.

Tuesday, October 26, 2004

2:30 PM- 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543